Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Precigen News

    1,289 € +0,31% +0,004 €
    08:43:32 Uhr Frankfurt aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2PZG1
    ISIN: US74017N1054
    US-Symbol: PGEN
    Typ: Aktie

    Precigen News

    24.04.24 - PR Newswire
    Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
    Precigen to Present Late-​breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory ...
    24.04.24 - PR Newswire
    Actym Therapeutics Appoints Thomas Smart as CEO
    Actym Therapeutics Appoints Thomas Smart as CEO PR Newswire
    28.03.24 - PR Newswire
    Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
    Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th PR Newswire
    19.03.24 - PR Newswire
    Precigen Reports Full Year 2023 Financial Results and Business Updates
    Precigen Reports Full Year 2023 Financial Results and Business Updates PR Newswire
    12.03.24 - PR Newswire
    Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
    Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory ...
    05.03.24 - PR Newswire
    Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
    Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th PR Newswire
    06.02.24 - PR Newswire
    Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference PR Newswire
    16.01.24 - PR Newswire
    Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
    Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission PR Newswire
    08.01.24 - PR Newswire
    Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference
    Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire
    18.12.23 - PR Newswire
    Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire
    29.11.23 - PR Newswire
    Precigen to Participate in the JMP Securities Hematology and Oncology Summit
    Precigen to Participate in the JMP Securities Hematology and Oncology Summit PR Newswire
    09.11.23 - PR Newswire
    Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs
    Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs PR Newswire
    07.11.23 - PR Newswire
    Precigen to Participate in the Stifel 2023 Healthcare Conference
    Precigen to Participate in the Stifel 2023 Healthcare Conference PR Newswire
    19.09.23 - PR Newswire
    Precigen to Participate in Upcoming Leading Investor and Industry Conferences
    Precigen to Participate in Upcoming Leading Investor and Industry Conferences PR Newswire
    14.08.23 - PR Newswire
    Levi & Korsinsky LLP notifies shareholders of BMRN, MAXR, SYF, PGEN of pending class action settlements
    Levi & Korsinsky LLP notifies shareholders of BMRN, MAXR, SYF, PGEN of pending class action settlements PR Newswire
    09.08.23 - PR Newswire
    Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025
    Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash ...
    09.08.23 - PR Newswire
    Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval
    Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval ...
    03.08.23 - PR Newswire
    Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th
    Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th PR Newswire
    20.06.23 - PR Newswire
    Thinking about buying stock in Cano Health, Dragonfly Energy Holdings, Lordstown Motors, Precigen, or Applied Optoelectronics?
    Thinking about buying stock in Cano Health, Dragonfly Energy Holdings, Lordstown Motors, Precigen, or Applied Optoelectronics? PR Newswire
    20.06.23 - PR Newswire
    Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
    Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis PR Newswire

    Newssuche

    Videos

    08:40 Uhr +17,83%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »